2019
Safety of Intravenous Arginine Therapy in Children with Sickle Cell Disease Hospitalized for Vaso-Occlusive Pain: A Randomized Placebo-Controlled Trial in Progress
Morris C, Figueroa J, Watt A, Khemani K, Kumari P, Barnett M, Bakshi N, Lane P, Dampier C. Safety of Intravenous Arginine Therapy in Children with Sickle Cell Disease Hospitalized for Vaso-Occlusive Pain: A Randomized Placebo-Controlled Trial in Progress. Blood 2019, 134: 995. DOI: 10.1182/blood-2019-122983.Peer-Reviewed Original ResearchVaso-occlusive pain episodesSickle cell diseaseChildren's Hospital OaklandRe-hospitalization rateAdverse eventsSerious AEsArginine bioavailabilityTreatment armsStandard dosePain scoresArginine therapyOpioid useStudy armsUnique patientsCell diseaseInpatient unitTreatment of SCDGrowth hormone stimulation testingGlobal arginine bioavailabilityIntravenous L-arginineLow arginine bioavailabilityParenteral opioid usePhase 2 RCTVaso-occlusive painPlacebo-controlled trial
2016
The role of the arginine metabolome in pain: implications for sickle cell disease
Bakshi N, Morris C. The role of the arginine metabolome in pain: implications for sickle cell disease. Journal Of Pain Research 2016, Volume 9: 167-175. PMID: 27099528, PMCID: PMC4821376, DOI: 10.2147/jpr.s55571.Peer-Reviewed Original ResearchSickle cell diseaseVaso-occlusive painArginine metabolomeArginine therapyArginine bioavailabilityLeg ulcersCell diseaseAcute vaso-occlusive painNitric oxidePhase II clinical trialGlobal arginine bioavailabilitySubset of patientsHallmark of SCDPreliminary clinical studyPromising therapeutic targetSemiessential amino acidPulmonary complicationsSCD painPulmonary hypertensionEndothelial dysfunctionPain severityPain mechanismsChronic painEarly mortalityPotent vasodilator